<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        263-212-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIRCERA 150MCG-0.3ML SOLN. FOR INJ
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1334.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ROCHE DIAGNOSTICS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ROCHE DIAGNOSTICS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B03XA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Methoxy polyethylene glycol-epoetin beta
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: methoxy polyethylene glycol-epoetin beta (produced by recombinant DNA
technology in Chinese hamster ovary [CHO] cells)
Excipients:
Sodium dihydrogen phosphate monohydrate, anhydrous sodium sulphate, mannitol, L-methionine,
poloxamer 188, hydrochloric acid, sodium hydroxide, water for injection q.s. 0.3 ml of solution,
corresponding to 0.62 mg of sodium.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MIRCERA 30 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 30 μg methoxy polyethylene
glycol-epoetin beta.
MIRCERA 50 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 50 μg methoxy polyethylene
glycol-epoetin beta.
MIRCERA 75 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 75 μg methoxy polyethylene
glycol-epoetin beta.
MIRCERA 100 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 100 μg methoxy
polyethylene glycol-epoetin beta.
MIRCERA 120 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 120 μg methoxy
polyethylene glycol-epoetin beta.
MIRCERA 150 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 150 μg methoxy
polyethylene glycol-epoetin beta.
MIRCERA 200 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 200 μg methoxy
polyethylene glycol-epoetin beta.
MIRCERA 250 μg/0.3 ml solution for injection in prefilled syringe
Each prefilled syringe with ready-to-use solution for injection contains 250 μg methoxy
polyethylene glycol-epoetin beta.
The quoted dosage strength in μg refers to the protein moiety of the methoxy polyethylene glycolepoetin
beta molecule without consideration of glycosylation.
MIRCERA is a clear, colorless to pale yellow solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of symptomatic renal anemia associated with chronic kidney disease (CKD) in dialyzed<br />or nondialyzed adult patients.<br />The safety and efficacy of MIRCERA therapy have not been established in other indications.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dosage</strong><br />Treatment with MIRCERA must be initiated under the supervision of a physician experienced in the<br />management of patients with renal impairment.<br />Treatment of symptomatic anemia in CKD patients<br />Patients should be monitored closely to ensure that the lowest approved effective dose of<br />MIRCERA is used to adequately control the symptoms of anemia while maintaining a hemoglobin<br />level at or below 12 g/dl (7.5 mmol/l). Caution should be exercised when increasing MIRCERA<br />doses in patients with chronic renal failure. In patients with a poor hemoglobin response to<br />MIRCERA, various causes for the poor response should be investigated (see Warnings and<br />precautions and Properties/Effects).<br />Anemia symptoms and sequelae may vary with age, gender and overall disease severity; evaluation<br />of the individual patient&rsquo;s clinical course and condition by a physician is therefore necessary.<br />MIRCERA should be administered either subcutaneously or intravenously to increase hemoglobin<br />to no higher than 12 g/dl (7.45 mmol/l). In patients not receiving hemodialysis, subcutaneous use is<br />preferable to avoid puncturing peripheral veins.<br />MIRCERA can be injected subcutaneously in the abdomen, arm or thigh. All three injection sites<br />are equally suitable for subcutaneous injection of MIRCERA.<br />Because of intraindividual variations between patients, hemoglobin values above or below the<br />desired level may occasionally be observed. Such hemoglobin variations can be offset by dose<br />adjustment, taking account of the hemoglobin target range of 10 g/dl (6.21 mmol/l) to 12 g/dl (7.45<br />mmol/l). A sustained hemoglobin level of greater than 12 g/dl (7.45 mmol/l) should be avoided;<br />guidelines for appropriate dose adjustment when hemoglobin values exceed 12 g/dl (7.45 mmol/l)<br />are described below.<br />A rise in hemoglobin of greater than 2 g/dl (1.24 mmol/l) over a four-week period should be<br />avoided. If it occurs, appropriate dose adjustment should be undertaken as specified.<br />Patients should be monitored closely to ensure use of the lowest approved dose of MIRCERA that<br />adequately controls the symptoms of anemia.</p><p>It is recommended that hemoglobin levels be monitored every two weeks until stabilized and at<br />regular intervals thereafter.<br />As recommended in current guidelines, the rate of increase in Hb and the target Hb should be<br />determined for each patient individually. In CKD patients, the aim of treatment is to reach a target<br />Hb level of 10-12 g/dl. Patients should be monitored closely to ensure that the lowest effective dose<br />of Mircera is used to provide adequate control of the symptoms of anaemia.<br />Initiation of treatment<br />Patients not currently treated with an erythropoiesis-stimulating agent (ESA):<br />Patients not on dialysis &ndash; The recommended starting dose is 1.2 &mu;g/kg body weight administered<br />once monthly as a single subcutaneous injection. Alternatively a starting dose of 0.6 &mu;g/kg body<br />weight may be administered once every two weeks as a single i.v. or s.c. injection.<br />Patients on dialysis &ndash; The recommended starting dose of 0.6 &mu;g/kg body weight may be<br />administered once every two weeks as a single i.v. or s.c. injection.<br />Dose adjustment<br />The MIRCERA dose may be increased by approximately 25% of the previous dose if the rise in<br />hemoglobin is less than 1.0 g/dl (0.621 mmol/l) over a month. Further dose increases of<br />approximately 25% may be made every 4 weeks until the individual target hemoglobin level is<br />achieved.<br />If the rise in hemoglobin exceeds 2 g/dl (1.24 mmol/l) in one month or if the hemoglobin level<br />exceeds 12 g/dl, the dose should be reduced by approximately 25%. If the hemoglobin level<br />continues to increase, therapy should be interrupted until the hemoglobin level begins to decrease,<br />at which point therapy should be restarted at a dose approximately half the previously administered<br />dose. After dose interruption a hemoglobin decrease of approximately 0.35 g/dl (0.22 mmol/l) per<br />week is expected. Dose adjustments should not be made more frecuently than once a month.<br />In patients treated once every two weeks whose hemoglobin concentration is above the target range,<br />may receive MIRCERA once monthly at twice the dose previously administered once every two<br />weeks.<br />Switching from erythropoiesis stimulating agent (ESA) treatment to Mircera<br />Patients currently treated with an ESA, can be switched to MIRCERA administered once a month<br />as a single intravenous or subcutaneous injection. The starting dose of MIRCERA is calculated<br />from the previous weekly ESA dose at the time of the treatment switch, as described in Table 1. The<br />first MIRCERA injection should be given at the time of the next scheduled dose of the previously<br />administered darbepoetin alfa or epoetin.</p><p><strong>Table 1. MIRCERA starting doses</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Previous weekly darbepoetin alfa i.v. or s.c. dose (&micro;g/week)</td><td>Previous weekly epoetin i.v. or s.c. dose (IU/week)</td><td>Monthly MIRCERA i.v. or s.c. dose (&micro;g/once monthly)</td></tr><tr><td>&lt;40</td><td>&lt;8000</td><td>120</td></tr><tr><td>40&ndash;80</td><td>8000&ndash;16,000</td><td>200</td></tr><tr><td>&gt;80</td><td>&gt;16,000</td><td>360</td></tr></tbody></table><p>If a dose adjustment is required to maintain the target hemoglobin concentration above 10 g/dl (6.21<br />mmol/l), the dose may be increased by approximately 25%.<br />If the rise in hemoglobin levels exceeds 2 g/dl (1.24 mmol/l) in one month or if the hemoglobin<br />level exceeds 12 g/dl, the dose should be reduced by approximately 25%. If the hemoglobin level<br />continues to increase, therapy should be interrupted until the hemoglobin level begins to decrease,<br />at which point therapy should be restarted at a dose approximately half the previously administered<br />dose. After dose interruption a haemoglobin decrease of approximately 0.35 g/dl (0.22 mmol/l) per<br />week is expected. Dose adjustments should not be made more frequently than once a month.<br />To ensure the traceability of biological medicinal products, it is recommended that the trade name<br />and batch number be documented with every treatment.<br />Special dosage instructions<br />Patients with hepatic impairment<br />No adjustments of the starting dose or dose modification rules are required in patients with any<br />degree of hepatic impairment (see &ldquo;Kinetics in specific patient groups&rdquo;).<br />Elderly patients<br />In clinical studies, 24% of patients treated with MIRCERA were 65 to 74 years old and 20% were<br />75 years or older. No dose adjustment is necessary in patients aged &ge;65 years.<br />Children and adolescents<br />Due to limited safety and efficacy data, no dosage recommendations can be given for use in patients<br />under 18 years of age.<br />Delayed administration<br />If a dose of Mircera is missed, the missed dose should be administered as soon as possible and<br />treatment with Mircera continued at the prescribed dosing frequency.<br />Mode of administration<br />Intravenous and subcutaneous administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed under “Composition”.
MIRCERA must not be used in patients with untreated or poorly controlled hypertension.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hemoglobin target levels above 12 g/dl may be assosiated with an increased risk of cardiovascular<br />events, including death. Controlled clinical studies have shown no significant benefit attributable to<br />epoetin use when the hemoglobin level is higher than that necessary to control symptoms of anemia<br />and avoid blood transfusion.<br />Patients with chronic renal failure<br />Caution should be exercised when increasing MIRCERA doses in patients with chronic renal failure<br />since high cumulative epoetin doses may be associated with an increased risk of mortality and<br />serious cardiovascular and cerebrovascular events. In patients with a poor hemoglobin response to<br />epoetins, various causes for the poor response should be investigated (see Dosage/Administration<br />and Properties/Effects<br />Iron supplementation<br />To ensure effective erythropoiesis, iron status should be determined in all patients before and during<br />treatment. As a rule, supplemental iron therapy should be given in accordance with current<br />treatment guidelines.<br />Failure to respond to MIRCERA therapy should prompt an immediate search for causative factors.<br />Deficiencies of iron, folic acid or vitamin B12 reduce the effectiveness of ESAs and should therefore<br />be corrected. Intercurrent infections, inflammatory or traumatic episodes, occult blood loss,<br />hemolysis, severe aluminium toxicity, underlying hematological disease or bone marrow fibrosis<br />may also compromise the erythropoietic response. A reticulocyte count should be considered as part<br />of the evaluation.<br />If all the conditions mentioned are excluded and the patient has a sudden drop of hemoglobin<br />associated with reticulocytopenia and antierythropoietin antibodies, examination of the bone<br />marrow for the diagnosis of pure red cell aplasia [PRCA] should be considered. If PRCA is<br />diagnosed, therapy with Mircera must be discontinued and patients must not be switched to another<br />ESA.<br />Pure red cell aplasia (PRCA)<br />Pure red cell aplasia due to antierythropoietin antibodies has been reported during treatment with<br />ESAs, including MIRCERA. These antibodies cross-react with all ESAs, and patients suspected or<br />confirmed to have antibodies to erythropoietin must not be switched to Mircera.<br />Blood pressure monitoring<br />As with other ESAs, blood pressure may rise during treatment with MIRCERA. Blood pressure<br />should be adequately monitored in all patients before, at initiation of and during treatment with<br />MIRCERA. If high blood pressure is difficult to control by medication or diet, MIRCERA must be<br />reduced in dose or withheld (see Contraindications).<br />SCAR<br />Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic<br />epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in<br />association with epoetin treatments. More severe cases have been observed with long-acting<br />epoetins.<br />At the time of prescription, patients should be advised of the signs and symptoms and monitored<br />closely for skin reactions. Typical signs include fever, a spreading painful rash that is often<br />preceded by fever and flu-like symptoms, blistering, and inflammation of the eyes and mucous</p><p>membranes. If signs and symptoms suggestive of such hypersensitivity reactions appear, Mircera<br />should be discontinued immediately.<br />If a patient has developed a severe skin reaction such as SJS or TEN due to the use of Mircera,<br />treatment with Mircera must not be restarted in this patient at any time.<br />Effect on tumor growth<br />MIRCERA, like other ESAs, is a growth factor that primarily stimulates erythrocyte production.<br />Erythropoietin receptors may be expressed on the surface of a variety of tumor cells. As with all<br />growth factors, there is a concern that ESAs could stimulate the growth of certain types of<br />malignancy. MIRCERA is not approved for the treatment of anemia in cancer patients.<br />Other<br />The safety and efficacy of MIRCERA therapy have not been investigated in patients with<br />hemoglobinopathies, seizure disorders, bleeding or a recent history of bleeding requiring<br />transfusions or with platelet counts above 500 &times; 109/l. Caution is therefore required in these<br />patients.<br />Misuse<br />Misuse by non-anaemic persons (e.g. for doping) may lead to an excessive increase in hemoglobin.<br />This carries a risk of life-threatening cardiovascular complications (risk of thrombosis due to<br />hemoconcentration in erythrocytosis).<br />Hemoglobin concentration<br />In CKD patients the maintenance hemoglobin concentration should not persistently exceed the<br />upper limit of the target hemoglobin concentration recommended under Dosage/Administration. In<br />clinical trials an increased risk of death and serious cardiovascular events was observed when<br />erythropoiesis stimulating agents (ESAs) were administered to achieve a target hemoglobin of<br />greater than 12 g/dl (7.5 mmol/l).<br />Controlled clinical trials have not shown significant benefits attributable to the administration of<br />epoetins when the hemoglobin concentration is increased beyond the level necessary to control<br />symptoms of anemia and to avoid blood transfusion.<br />This medicinal product contains less than 1 mmol of sodium (23 mg) per prefilled syringe, i.e. it is<br />virtually &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. Clinical studies have produced no evidence that<br />MIRCERA interacts with other medicinal products. The effect of other drugs on the MIRCERA<br />pharmacokinetics and pharmacodynamics was investigated in a population analysis. No evidence<br />was found of an effect on MIRCERA pharmacokinetics or pharmacodynamics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are insufficient data on use in pregnant women.<br />Animal studies have shown no direct or indirect toxicity affecting pregnancy, embryonic<br />development, fetal development, parturition (see Preclinical data) and/or postnatal development.<br />Caution is required if used during pregnancy.</p><p>Lactation<br />It is unknown whether methoxy polyethylene glycol-epoetin beta is excreted in human breast milk.<br />One animal study has shown excretion of methoxy polyethylene glycol-epoetin beta in maternal<br />milk. In deciding whether to continue or discontinue breastfeeding during treatment with<br />MIRCERA or to discontinue MIRCERA, the benefit of breastfeeding to the child should be<br />weighed against the benefit of MIRCERA therapy to the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MIRCERA has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The MIRCERA safety data from clinical trials are based on 3042 CKD patients, including 1939<br />patients treated with MIRCERA and 1103 with another ESA. Undesirable effects must be expected<br />in some 6% of patients treated with MIRCERA. The most frequent reported undesirable effect was<br />hypertension (common).</p><p><strong>Table 2. Undesirable effects attributed to MIRCERA treatment in controlled clinical trials in CKD patients</strong></p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Organ class</td><td style="width:87px">Frequency</td><td style="width:226px">Adverse reaction</td></tr><tr><td>Vascular&nbsp;disorders</td><td style="width:87px">Common</td><td style="width:226px">Hypertension</td></tr><tr><td>General disorders and<br />administration site conditions</td><td style="width:87px">Uncommon</td><td style="width:226px">Vascular-access thrombosis</td></tr><tr><td>Nervous system&nbsp;disorders</td><td style="width:87px">Uncommon<br />Rare</td><td style="width:226px">Headache<br />Hypertensive encephalopathy</td></tr><tr><td>Skin and subcutaneous tissue<br />disorders</td><td style="width:87px">Rare</td><td style="width:226px">Rash (maculopapular, severe),<br />skin exfoliation, erythema<br />multiforme, Stevens-Johnson<br />syndrome (SJS), toxic epidermal<br />necrolysis (TEN)</td></tr><tr><td>Immune system disorders</td><td style="width:87px">Rare</td><td style="width:226px">Hypersensitivity</td></tr></tbody></table><p>All other reactions attributed to MIRCERA were rare and in most cases mild to moderate in<br />severity. These reactions could be explained by comorbidities known in the population.<br />In clinical studies, the platelet count decreased slightly during treatment with MIRCERA, but<br />remained within the normal range.<br />Platelet counts below 100 &times; 109/l were observed in 7.5% of patients treated with MIRCERA and<br />4.4% of patients treated with ESAs.<br />The safety profile in the paediatric population was consistent with that in adults.<br />Undesirable effects after market launch<br />Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic<br />epidermal necrolysis (TEN), skin exfoliation and erythema multiforme, have been reported with<br />Mircera in the post-marketing setting (see &ldquo;Warnings and precautions&rdquo;). Frequencies are not<br />known.</p><p>The occurrence of neutralizing antierythropoietin antibody-mediated pure red cell aplasia (AEABPRCA)<br />has been reported in association with MIRCERA therapy during post-marketing experience<br />(see Warnings and precautions).<br />Description of selected adverse reactions<br />Reporting of suspected adverse reactions after marketing authorisation is very important. It allows<br />continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals<br />are asked to report any suspected new or serious adverse reaction.</p><p><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />&bull; SFDA call center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p><strong>&bull; Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&minus; Please contact the relevant competent authority.</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MIRCERA has a wide therapeutic range. Individual response must be considered when initiating<br />treatment with MIRCERA.<br />Signs and symptoms<br />Overdose can result in an exaggerated pharmacodynamic effect, e.g. excessive erythropoiesis.<br />Treatment<br />In case of excessive haemoglobin levels, Mircera should be temporarily withheld (see<br />&ldquo;Dosage/Administration&rdquo;).<br />If clinically indicated, phlebotomy may be performed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: B03XA03</p><p>Mechanism of action<br />Mircera stimulates erythropoiesis by interaction with the erythropoietin receptor on progenitor cells<br />in the bone marrow. As primary growth factor for erythroid development, the natural hormone<br />erythropoietin is produced by the kidney and released into the bloodstream according to the level of<br />tissue oxygen saturation. In response to hypoxia, the natural hormone erythropoietin interacts with<br />erythroid progenitor cells, increasing their production.<br />Pharmacodynamics<br />Methoxy polyethylene glycol-epoetin beta, the active substance of MIRCERA, is a continuous<br />erythropoietin receptor activator that differs from erythropoietin in its activity at the receptor level,<br />which is characterized by slower association with and faster dissociation from the receptor, reduced<br />specific activity in vitro with increased activity in vivo, and an increased half-life. Its average<br />molecular weight is about 60 kDa, of which the protein portion plus carbohydrate portion accounts<br />for approximately 30 kDa.<br />Clinical efficacy<br />In two randomized controlled studies in patients with chronic renal disease not on dialysis,<br />BA16738 and NH20052, MIRCERA corrected anemia in 97.5% and 94.1% of the patients,<br />respectively. In study BA16738, the proportion of patients with a hemoglobin level exceeding<br />13 g/dl in the first 8 treatment weeks was 11.4% in the MIRCERA group and 34% in the<br />darbepoetin alfa group. In study NH20052, the proportion of patients with a hemoglobin level<br />exceeding 12 g/dl was 25.8% in the MIRCERA group and 47.7% in the darbepoetin alfa group. In<br />the randomized controlled study in chronic renal failure with dialysis, MIRCERA corrected anemia<br />in 93.3% of patients.<br />Four randomized controlled studies were performed in dialysis patients currently treated with ESAs.<br />Patients were randomized to stay on their current treatment or be switched to MIRCERA in order to<br />achieve stable hemoglobin levels. In the evaluation period (weeks 29&ndash;36), mean and median<br />hemoglobin levels in patients in the MIRCERA group were virtually identical to their baseline<br />levels.<br />In a randomized study of epoetin beta in predialysis patients (CREATE), in which 603 patients with<br />renal anemia were assigned to a group with either high (13&ndash;15 g/dl) or low (10.5&ndash;11.5 g/dl) target<br />hemoglobin levels, the frequency of cardiovascular events in the group with higher hemoglobin<br />levels was 19% vs 16% in the lower target hemoglobin group (58 vs 47 cases; p=0.20). The<br />frequency of thromboembolic events in this study was 11% in the high target hemoglobin group and<br />7% in that with a low target hemoglobin as the treatment goal (p=0.06). As reported earlier, the<br />frequency of vascular-access thrombosis in patients referred for dialysis was likewise higher in<br />those with a high hemoglobin level as the treatment goal (4% vs 3%; p=0.42).<br />In a randomized study of epoetin alfa in predialysis patients (CHOIR), in which 1432 patients were<br />assigned to a study arm with a high target hemoglobin level (13.5 g/dl) or one with a low target<br />hemoglobin level (11.5 g/dl), there were significantly more cardiovascular events in the high target<br />hemoglobin group than in the group with low target hemoglobin levels (17% vs 14%; 125 vs 97</p><p>cases; p=0.03). The frequency of thromboembolic events in the high-hemoglobin study arm was<br />18% vs 17% in the low-hemoglobin arm (p=0.65).<br />In the MIRCERA development program, no study was performed to compare high and low target<br />hemoglobin levels in a similar patient population.<br />Safety and efficacy in paediatric patients<br />A phase II, dose-finding, open-label, repeated-dose, multicentre study was conducted in 64<br />paediatric haemodialysis patients (5 to 17 years old) with CKD to determine the effective starting<br />dose of Mircera i.v. when switching from maintenance treatment with another ESA (epoetin<br />alfa/beta or darbepoetin alfa). The primary efficacy endpoint in this study (change in Hb<br />concentration [g/dl] between the baseline and evaluation periods) has been met.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic and pharmacological properties of MIRCERA make it possible to treat<br />patients with a once-monthly regimen, thanks to its long elimination half-life. After intravenous<br />dosing, MIRCERA has an elimination half-life 15 to 20 times longer than that of recombinant<br />human erythropoietin.<br />The pharmacokinetics of MIRCERA were studied in healthy volunteers and in anemic dialyzed and<br />nondialyzed CKD patients.<br />The clearance and volume of distribution of MIRCERA in the CKD patients were not dosedependent.<br />MIRCERA pharmacokinetics were studied in CKD patients after the first dose and after dosing in<br />week 9 and week 19 or 21. Repeated administration had no effects on the clearance, volume of<br />distribution or bioavailability of MIRCERA. Four-weekly administration in CKD patients led to<br />virtually no accumulation of MIRCERA, as shown by the accumulation ratio of 1.03. After 2-<br />weekly administration the accumulation ratio was 1.12.<br />Comparison of MIRCERA serum concentrations measured before and after hemodialysis in 41<br />CKD patients showed that hemodialysis had no effect on the drug&rsquo;s pharmacokinetics.<br />An analysis in 126 CKD patients showed no pharmacokinetic difference between dialyzed and<br />nondialyzed patients.<br />Absorption<br />Following subcutaneous administration to CKD patients, the maximum serum concentrations of<br />methoxy polyethylene glycol-epoetin beta were observed 72 hours (median value) after<br />administration in dialyzed patients and 95 hours after administration in patients not on dialysis.<br />The absolute bioavailability of methoxy polyethylene glycol-epoetin beta after s.c. administration<br />was 62% and 54%, in dialysis patients and patients not on dialysis, respectively.<br />Distribution<br />A study in 400 CKD patients showed that MIRCERA has a volume of distribution of approximately<br />5 l.<br />Metabolism<br />No information.</p><p>Elimination<br />Following intravenous administration to CKD patients, the half-life of MIRCERA was 134 hours<br />(5.6 days) and the total systemic clearance was 0.494 ml/h per kg. Following subcutaneous<br />administration, the terminal half-life was 139 hours (5.8 days) in CKD patients on dialysis and 142<br />hours in patients not on dialysis.<br />Kinetics in specific patient groups<br />Hepatic impairment<br />Mircera pharmacokinetics in patients with severe liver failure are similar to those in healthy<br />subjects (see Special dosage instructions).<br />Renal impairment<br />Pooled post hoc analyses of clinical studies with erythropoiesis-stimulating agents (ESAs) have<br />been performed in chronic renal failure patients (dialysis patients, diabetics and nondiabetics). With<br />higher cumulative ESA doses, a trend towards increased risk event probabilities for all-cause<br />mortality and cardiovascular and cerebrovascular events was observed, independently of diabetes or<br />dialysis status (see Dosage/Administration and Warnings and precautions).<br />Children and adolescents The pharmacokinetics of Mircera were studied in 64 paediatric CKD<br />patients (5 to 17 years old) receiving haemodialysis. At steady state (after the third dose of<br />Mircera), a Cmax of 66.1 ng/ml and AUC0 tau of 7170 ng.hr/ml (both geometric means) were<br />measured as the maximum observed exposure. Subsequently, Mircera serum concentrations<br />declined with an apparent mean half-life of approximately 121 to 147 hours (geometric mean) in a<br />manner similar to that in adults.<br />Other special populations<br />Population analyses found no evidence that age, gender or ethnicity have a relevant<br />pharmacokinetic effect. A population-based pharmacokinetic analysis likewise showed no relevant<br />difference in pharmacokinetics between dialyzed and nondialyzed patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data based on conventional studies of cardiovascular safety pharmacology, repeateddose<br />toxicity, reproductive toxicity and carcinogenic potential show no special hazard for humans.<br />Carcinogenicity<br />The carcinogenic potential of MIRCERA has not been evaluated in long-term animal studies.<br />MIRCERA did not induce a proliferative response in nonhematological tumor cell lines in vitro. In<br />a six-month rat toxicity study, no mitogenic or tumorigenic responses were observed in<br />nonhematological tissues.<br />Reproductive toxicity<br />Animal studies produced no evidence of adverse effects on pregnancy, embryofetal development or<br />delivery. Peri-postnatal studies showed reduced weight gain in neonates. Subcutaneous<br />administration of MIRCERA to male and female rats before and during mating had no effect on<br />reproductive performance, fertility or sperm parameters.</p><p>Additional data<br />In a panel of human tissues, in vitro binding of MIRCERA was only observed in target cells (bone<br />marrow progenitor cells).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, MIRCERA must not be mixed with other medicinal<br />products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>36 Months<br />Do not use this medicine after the expiry date (&ldquo;EXP&rdquo;) stated on the pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Store in a refrigerator (2°C–8° C).
Do not freeze.
Keep the container in the original carton in order to protect the contents from light.
Keep out of the reach of children.
Prefilled syringe
The patient can store the product outside the refrigerator at room temperature (up to 25°C) on one
occasion for up to 1 month. Once removed from the refrigerator, the product must be used within
this period.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The MIRCERA solution for injection in the prefilled syringe is ready for use. The sterile solution<br />for injection in the prefilled syringe contains no preservatives and is intended for a single injection<br />only. Only one dose should be administered per syringe. Only solutions that are clear, colorless to<br />pale yellow and free of visible particles may be injected.<br />Do not shake.<br />Allow the prefilled syringe to reach room temperature before injecting.<br />Dispose of any unused product or waste in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packs<br />Prefilled syringe containing 30 &mu;g in 0.3 ml: 1<br />Prefilled syringe containing 50 &mu;g in 0.3 ml: 1<br />Prefilled syringe containing 75 &mu;g in 0.3 ml: 1<br />Prefilled syringe containing 100 &mu;g in 0.3 ml: 1<br />Prefilled syringe containing 120 &mu;g in 0.3 ml: 1<br />Prefilled syringe containing 150 &mu;g in 0.3 ml: 1<br />Prefilled syringe containing 200 &mu;g in 0.3 ml: 1<br />Prefilled syringe containing 250 &mu;g in 0.3 ml: 1</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The MIRCERA prefilled syringe is ready for use. The prefilled syringe contains no preservatives and is intended for a single injection only. Only one dose should be administered per syringe. Only solutions that are clear, colourless to pale yellow and free of visible particles may be injected. Do not shake.&nbsp;Allow the prefilled syringe to reach room temperature before injecting. Dispose of any unused product or waste in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124,
CH-4070 Basel,
Switzerland.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>